Table 1 Patient and tumor characteristics by molecular subtype
From: Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer
Luminal-like | HER2 -rich | Triple negative | p | |
|---|---|---|---|---|
(n = 121, 49.2%) | (n = 80 , 32.5%) | (n = 45, 18.3%) | ||
Age | ||||
> 40 | 94 (77.7%) | 67(83.8%) | 36 (80%) | 0.5739 |
≤ 40 | 27 (22.3%) | 13(16.2%) | 9 (20%) | |
Menopause status | ||||
Premenopausal | 81 (66.9%) | 30(37.5%) | 22 (48.9%) | 0.0002 |
Postmenopausal | 40(33.1%) | 50(62.5%) | 23(51.1%) | |
Primary tumor size | ||||
cT1-3 | 56(46.3%) | 36(45.0%) | 23(51.1%) | 0.7974 |
cT4 | 65(53.7%) | 44(55.0%) | 22(48.9%) | |
Nuclear grade | ||||
Nuclear Grade 1-2 | 24(19.8%) | 9(11.3%) | 1(2.2%) | 0.0092* |
Nuclear Grade 3 | 35 (28.9%) | 28(35.0%) | 18 (40.0%) | |
unknown | 62(51.3%) | 43(53.7%) | 26(57.8%) | |
Lymphovascular invasion | ||||
No / Focal | 15(12.4%) | 14(17.5%) | 5(11.1%) | 0.22121* |
prominent | 30(24.8%) | 12(15.0%) | 9(20.0%) | |
unknown | 76(62.8%) | 54(67.5%) | 31(68.9%) | |
Lymph node status | ||||
No axillary LN involvement | 30 (24.8%) | 19(23.8%) | 8 (17.8%) | 0.6284 |
Axillary, IM, or SC LN involvement | 91(75.2%) | 61(76.2%) | 37(82.2%) | |
Tumor markers | ||||
Elevated CEA | 53 (43.8%) | 40(50.0%) | 15 (33.3%) | 0.2740* |
Elevated CA 15-3 | 71 (58.7%) | 34(42.5%) | 18 (40.0%) | 0.0063 |
Metastasis site at first diagnosis | ||||
Liver | 27 (22.3%) | 43(53.8%) | 18 (40%) | < 0.0001 |
Lung | 42 (34.7%) | 34(42.5%) | 18 (40%) | 0.5189 |
Brain | 15(12.4%) | 13(16.3%) | 8(17.8%) | 0.6041 |
Bone | 95 (78.5%) | 53(66.3%) | 26 (57.8%) | 0.0187 |
Treatments | ||||
Systemic chemotherapy | 106 (87.6%) | 76(95.0%) | 37 (82.2%) | 0.0705 |
Anti-hormonal treatment | 24 (19.8%) | 6(7.5%) | 1 (2.2%) | 0.0024 |
Local treatment to primary breast tumor | 62(51.2%) | 33(41.3%) | 18(40.0%) | 0.2571 |